CE
CELU.US Celularity Inc
- Market cap
- USD 20.4M
- P/E
- -
- P/B
- 9.89x
- ROE
- -
- Dividend yield
- 28.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CELU.US undervalued?
Graham numberThe Graham number of Celularity Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Celularity Inc fundamental analysis
No fundamental analysis for Celularity Inc yet.
Celularity Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Celularity Inc
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimm…
Full company profileCelularity Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Celularity Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 17.6M | 21.1M | 14.3M | 21.3M | 18.0M | 22.8M | 54.2M | 26.6M | 17.8M |
| Gross Profit | 11.0M | 14.8M | 9.35M | 11.7M | -1.69M | 6.76M | 39.2M | 6.48M | 2.95M |
| Operating Income | -1.10K | -264M | -152M | -109M | -25.6M | -76.5M | -38.4M | -61.3M | -48.6M |
| EBITDA | -1.10K | -71.0M | -202M | -88.1M | -139M | -184M | -43.7M | -77.7M | -21.9M |
| Net Income | -1.10K | -212M | -208M | -100M | 14.2M | -196M | -57.9M | -91.7M | -30.4M |
| EPS | 0.00 | -89 | -113 | -7.87 | 0.95 | -10 | -2.64 | -3.58 | -1.04 |
| Balance Sheet | |||||||||
| Total Assets | 24.7K | 521M | 431M | 414M | 401M | 144M | 133M | 107M | 96.2M |
| Total Liabilities | 151K | 384M | 412M | 315M | 202M | 103M | 124M | 145M | 132M |
| Shareholders' Equity | -126K | 138M | 18.7M | 99.4M | 199M | 41.0M | 8.84M | -38.1M | -35.5M |
| Cash & Short-term Investments | 24.7K | 28.1M | 54.3M | 37.2M | 14.0M | 227K | 738K | 6.18M | 586K |
| Total Debt | 150K | 28.1M | 30.6M | 31.1M | 65.6M | - | 68.8M | 40.9M | 36.0M |
| Cash Flow | |||||||||
| Operating Cash Flow | -543.00 | -1.10M | -63.2M | -110M | -138M | -38.7M | -6.40M | -13.3M | -6.35M |
| Capital Expenditure | 1.92M | 3.00 | 27.8M | 6.20M | 5.24M | 4.05M | 161K | 0.00 | 0.00 |
| Free Cash Flow | -1.92M | -1.10M | -91.0M | -116M | -143M | -42.7M | -6.56M | -13.3M | -6.35M |
| Ratios | |||||||||
| ROE | - | -153.7% | -1,112.8% | -100.7% | 7.1% | -479.2% | -655.1% | - | - |
| ROA | -4.4% | -40.6% | -48.3% | -24.2% | 3.5% | -136.4% | -43.6% | -85.5% | -31.6% |
| Net Profit Margin | 0.0% | -1,001.9% | -1,458.4% | -469.3% | 79.0% | -862.0% | -106.8% | -345.4% | -170.2% |
| Debt to Equity | - | 0.20x | 1.64x | 0.31x | 0.33x | - | 7.79x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Celularity Inc dividends
- Dividend yield
- 28.85%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.90M | 0.23 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 39.1M | 2.61 | 275.3% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Feb 29, 2024.
Who owns Celularity Inc
- Insiders 33.27%
- Institutions 11.73%
- Public & others 55.00%
- Shares outstanding 32.5M
- Free float 22.5M
Top funds holding CELU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 455K | 1.40% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 86.6K | 0.27% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 21.2K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 20.7K | 0.06% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.32K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.59K | 0.00% | 0.00% | Aug 2026 |
Top institutions holding CELU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| C V Starr & Co Inc | 764K | 2.35% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 621K | 1.91% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 167K | 0.52% | -12.52% | Jun 2026 |
| Citadel Advisors Llc | 99.1K | 0.31% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 79.9K | 0.25% | 0.00% | Jun 2026 |
| BlackRock Inc | 76.4K | 0.24% | -40.11% | Jun 2026 |
| State Street Corp | 57.8K | 0.18% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 56.6K | 0.17% | +342.67% | Jun 2026 |
| Northern Trust Corp | 44.2K | 0.14% | 0.00% | Jun 2026 |
| Biltmore Family Office, LLC | 35.0K | 0.11% | 0.00% | Sep 2026 |
| HB Wealth Management, LLC | 31.9K | 0.10% | -21.03% | Jun 2026 |
| Keynote Financial Services, LLC | 29.9K | 0.09% | +2.05% | Jun 2026 |
| Jane Street Group LLC | 28.7K | 0.09% | 0.00% | Jun 2026 |
| CenterStar Asset Management, LLC | 21.0K | 0.06% | +17.65% | Jun 2026 |
| Virtu Financial LLC | 18.7K | 0.06% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 18.0K | 0.06% | 0.00% | Jun 2026 |
| Ipg Investment Advisors, LLC | 17.2K | 0.05% | 0.00% | Jun 2026 |
| IFP Advisors, LLC | 12.0K | 0.04% | +50.00% | Jun 2026 |
| Tower Research Capital LLC | 5.11K | 0.02% | +56.59% | Jun 2026 |
| Group One Trading, LLC | 3.60K | 0.01% | +3,684.21% | Jun 2026 |
Celularity Inc company profile
- Company name
- Celularity Inc
- Ticker
- CELU.US
- Exchange
- USA Stocks
- Listed since
- Aug 8, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 115
- Fiscal year end
- December
- Address
- 170 Park Avenue, Florham Park, NJ, United States, 07932
- Phone
- 908 768 2170
- Website
- celularity.com
About Celularity Inc
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Celularity Inc management
8- Dr. Robert Joseph Hariri M.D., Ph.D.Founder, CEO & Chairman · born 1959
- Mr. John M. SpragueChief Financial Officer
- Mr. Steven N. Gordon Esq.Chief Operating and Administrative Officer & Director
- Mr. Carlos RamirezSVP of Investor Relations
- Mr. Kyle Harold Fletcher Esq.Chief Legal and Strategy Officer & Corporate Secretary · born 1985
- Sharmila Koppisetti M.D.Senior Vice President of Clinical Dev. Immunology & Drug Safety
- Mr. Tim WilkSenior Vice President of Technical Operations
- Mr. David Jakob Lemus CPA, M.S., MBATreasurer · born 1962